Xencor Appoints Todd Simpson to Board of Directors
Xencor (NASDAQ:XNCR) announced the appointment of Todd Simpson to its board of directors. Simpson brings over 40 years of experience in CFO roles and public accounting, most notably serving as CFO at Seagen Inc. until its 2023 acquisition.
During his 18-year tenure at Seagen, Simpson was instrumental in the development and commercialization of four oncology medicines across multiple indications in the US. He led the company's international expansion, resulting in the commercialization of three medicines in the Americas and Europe. His responsibilities included oversight of global finance, strategic planning, tax, treasury, corporate real estate, facilities, investor relations, corporate communications, and IT.
Simpson currently serves on the board of Shape Therapeutics and previously held board positions at Neoleukin Therapeutics, Aquinox Pharmaceuticals, and Life Science Washington. He is a certified public accountant and holds a B.S. in accounting and computer science from Oregon State University.
Xencor (NASDAQ:XNCR) ha annunciato la nomina di Todd Simpson nel suo consiglio di amministrazione. Simpson porta con sé oltre 40 anni di esperienza in ruoli di CFO e nella contabilità pubblica, avendo ricoperto in particolare la carica di CFO presso Seagen Inc. fino all'acquisizione nel 2023.
Durante il suo mandato di 18 anni in Seagen, Simpson è stato fondamentale nello sviluppo e nella commercializzazione di quattro farmaci oncologici per diverse indicazioni negli Stati Uniti. Ha guidato l'espansione internazionale dell'azienda, portando alla commercializzazione di tre farmaci nelle Americhe e in Europa. Le sue responsabilità includevano la supervisione delle finanze globali, la pianificazione strategica, la tassazione, la tesoreria, gli immobili aziendali, le strutture, le relazioni con gli investitori, le comunicazioni aziendali e l'IT.
Simpson attualmente fa parte del consiglio di Shape Therapeutics e ha precedentemente ricoperto posizioni nel consiglio di Neoleukin Therapeutics, Aquinox Pharmaceuticals e Life Science Washington. È un commercialista certificato e ha conseguito una laurea in contabilità e informatica presso l'Oregon State University.
Xencor (NASDAQ:XNCR) anunció el nombramiento de Todd Simpson en su junta directiva. Simpson aporta más de 40 años de experiencia en roles de CFO y contabilidad pública, destacándose como CFO en Seagen Inc. hasta su adquisición en 2023.
Durante su mandato de 18 años en Seagen, Simpson fue fundamental en el desarrollo y comercialización de cuatro medicamentos oncológicos para múltiples indicaciones en los EE. UU. Lideró la expansión internacional de la empresa, lo que resultó en la comercialización de tres medicamentos en las Américas y Europa. Sus responsabilidades incluían la supervisión de finanzas globales, planificación estratégica, impuestos, tesorería, bienes raíces corporativos, instalaciones, relaciones con inversores, comunicaciones corporativas y TI.
Simpson actualmente forma parte de la junta de Shape Therapeutics y anteriormente ocupó cargos en la junta de Neoleukin Therapeutics, Aquinox Pharmaceuticals y Life Science Washington. Es contador público certificado y tiene una licenciatura en contabilidad e informática de la Universidad Estatal de Oregón.
Xencor (NASDAQ:XNCR)는 Todd Simpson을 이사회에 임명했다고 발표했습니다. Simpson은 CFO 역할과 공공 회계에서 40년 이상의 경험을 가지고 있으며, 특히 2023년 인수될 때까지 Seagen Inc.의 CFO로 재직했습니다.
Seagen에서 18년 동안 재직하는 동안, Simpson은 미국 내 여러 적응증에 걸쳐 네 가지 항암제의 개발 및 상용화에 중요한 역할을 했습니다. 그는 회사의 국제적 확장을 이끌어 아메리카와 유럽에서 세 가지 의약품의 상용화를 이끌었습니다. 그의 책임에는 글로벌 재무, 전략 기획, 세무, 재무 관리, 기업 부동산, 시설, 투자자 관계, 기업 커뮤니케이션 및 IT 감독이 포함되었습니다.
Simpson은 현재 Shape Therapeutics의 이사로 재직 중이며, 이전에는 Neoleukin Therapeutics, Aquinox Pharmaceuticals 및 Life Science Washington의 이사직을 역임했습니다. 그는 공인 회계사이며 오리건 주립대학교에서 회계 및 컴퓨터 과학 학사 학위를 취득했습니다.
Xencor (NASDAQ:XNCR) a annoncé la nomination de Todd Simpson à son conseil d'administration. Simpson apporte plus de 40 ans d'expérience dans des rôles de CFO et dans la comptabilité publique, ayant notamment été CFO chez Seagen Inc. jusqu'à son acquisition en 2023.
Au cours de son mandat de 18 ans chez Seagen, Simpson a joué un rôle clé dans le développement et la commercialisation de quatre médicaments oncologiques pour plusieurs indications aux États-Unis. Il a dirigé l'expansion internationale de l'entreprise, ce qui a conduit à la commercialisation de trois médicaments en Amérique et en Europe. Ses responsabilités comprenaient la supervision des finances mondiales, la planification stratégique, la fiscalité, la trésorerie, l'immobilier d'entreprise, les installations, les relations avec les investisseurs, les communications d'entreprise et l'informatique.
Simpson siège actuellement au conseil de Shape Therapeutics et a précédemment occupé des postes au conseil d'administration de Neoleukin Therapeutics, Aquinox Pharmaceuticals et Life Science Washington. Il est expert-comptable certifié et détient un B.S. en comptabilité et en informatique de l'Université d'État de l'Oregon.
Xencor (NASDAQ:XNCR) gab die Ernennung von Todd Simpson in seinen Vorstand bekannt. Simpson bringt über 40 Jahre Erfahrung in CFO-Rollen und in der öffentlichen Rechnungslegung mit, insbesondere als CFO bei Seagen Inc. bis zur Übernahme im Jahr 2023.
Während seiner 18-jährigen Tätigkeit bei Seagen war Simpson maßgeblich an der Entwicklung und Vermarktung von vier onkologischen Medikamenten für verschiedene Indikationen in den USA beteiligt. Er leitete die internationale Expansion des Unternehmens, was zur Vermarktung von drei Medikamenten in Amerika und Europa führte. Zu seinen Verantwortlichkeiten gehörten die Aufsicht über die globale Finanzen, strategische Planung, Steuern, Treasury, Unternehmensimmobilien, Einrichtungen, Investorenbeziehungen, Unternehmenskommunikation und IT.
Simpson ist derzeit im Vorstand von Shape Therapeutics tätig und hatte zuvor Vorstandspositionen bei Neoleukin Therapeutics, Aquinox Pharmaceuticals und Life Science Washington inne. Er ist ein zertifizierter Wirtschaftsprüfer und hat einen B.S. in Rechnungswesen und Informatik von der Oregon State University.
- Addition of seasoned financial executive with 40+ years of experience
- New director brings successful track record in biotech commercialization
- Expertise in scaling biotech companies from development to commercial stage
- Strong background in global expansion and multi-product commercialization
- None.
“Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth companies in the biopharmaceutical industry. We are thrilled to welcome Todd to our Board, and we look forward to working with him,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor.
As Seagen’s CFO for 18 years, Mr. Simpson played an important role in the development, launch, and commercialization of four oncology medicines across more than a dozen labeled indications in
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313419179/en/
For Investors:
Charles Liles
cliles@xencor.com
(626) 737-8118
For Media:
Cassidy McClain
Inizio Evoke
cassidy.mcclain@inizioevoke.com
(619) 694-6291
Source: Xencor, Inc.
FAQ
What experience does Todd Simpson bring to Xencor's (XNCR) board of directors?
What were Todd Simpson's key achievements during his tenure at Seagen before joining XNCR?
What other board positions does XNCR's new director Todd Simpson currently hold?
What departments did Todd Simpson oversee as CFO before joining XNCR's board?
